This report describes a 21-year-old man in China with cystic fibrosis who had a Mycobacterium abscessus infection and a Staphylococcus aureus infection. He received a quadruple antimycobacterial regimen of linezolid, moxifloxacin, azithromycin, and minocycline, combined with systemic supportive care. The report states that he achieved clinical stability. No safety events were reported, and no comparator was used. The study is a single case and literature review, so its findings are very limited and not generalizable. The main reason to be careful is that this is one person, and the report does not detail follow-up or long-term outcomes. Readers should see this as an example of personalized antimicrobial strategy in a complex infection, not as a proven treatment. It highlights the importance of early recognition of cystic fibrosis and improved access to essential medications, but it does not change standard care.
Quadruple antimycobacterial regimen achieves clinical stability in cystic fibrosis patient with M. abscessusCase report shows quadruple regimen for cystic fibrosis infection
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This is a case report combined with a literature review from China, describing a 21-year-old man with cystic fibrosis (CF) who developed a pulmonary infection with Mycobacterium abscessus and Staphylococcus aureus. The patient was treated with a quadruple antimycobacterial regimen consisting of linezolid, moxifloxacin, azithromycin, and minocycline, along with systemic supportive care. The primary outcome of clinical stability was achieved.
The authors highlight the importance of early recognition of CF, personalized antimicrobial strategies, and improved access to essential medications. They note that limited access and financial constraints for CFTR modulator therapy remain significant barriers in this setting. No adverse events or follow-up duration were reported.
While this single-case report cannot provide generalizable evidence, it illustrates a potential treatment approach for M. abscessus infection in CF patients when CFTR modulators are unavailable. Clinicians should interpret these findings cautiously, as the evidence is limited to one patient and lacks a comparator or long-term outcomes.